Agilent Invests $80M in Lasergen | GenomeWeb

NEW YORK (GenomeWeb) – Agilent Technologies announced Monday that it has invested $80 million in next-generation sequencing technology firm Lasergen, with the ultimate goal of incorporating Lasergen's technology into a clinical sequencing workflow.

Agilent's investment gives it a 48 percent stake in Houston-based Lasergen and a seat on the board of directors. Under the terms of the deal, Agilent also has the option to acquire the smaller company's remaining shares for an additional $105 million. That option expires March 2, 2018.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.

Feb
23
Sponsored by
NuGEN

This webinar will discuss a project that sought to understand the parent-of-origin epigenetic mechanisms that regulate seed development in plants, with a particular emphasis on differentiating the maternal or paternal origin of epigenetics marks.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.